Isaac B. Thorman

Isaac B. Thorman

Auto-generated profile, based on publicly available information

Isaac B. Thorman

School of Medicine, New York Medical College, Valhalla, NY

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2026 in Epileptic Disorders
Verified
Journal Article
Closed access
ITIsaac B. Thorman
Isaac B. Thorman
ASAriel Sacknovitz
Ariel Sacknovitz
RWRichard Wang
Richard Wang
PMPatrica Engel McGoldrick
Patrica Engel McGoldrick
MSMichael C. Schubert
Michael C. Schubert
SWSteven Wolf
Steven Wolf

5 June 2026 in Annals of Neurology
Verified
Journal Article
Closed access
ITIsaac B. Thorman
Isaac B. Thorman
ASAriel Sacknovitz
Ariel Sacknovitz
ALAustin G. Li
Austin G. Li
AMAryan Malhotra
Aryan Malhotra
PMPatrica Engel McGoldrick
Patrica Engel McGoldrick
FAFawaz Al-Mufti
Fawaz Al-Mufti

13 August 2026 in Neurotherapeutics
Verified
Journal Article
Open access
ITIsaac B. Thorman
Isaac B. Thorman
ASAriel Sacknovitz
Ariel Sacknovitz
AGAnjali Goyal
Anjali Goyal
ALAustin G. Li
Austin G. Li
AMAryan Malhotra
Aryan Malhotra
FAFawaz Al-Mufti
Fawaz Al-Mufti

1 September 2026 in Stroke: Vascular and Interventional Neurology
Verified
Journal Article
Open access
ASAriel Sacknovitz
Ariel Sacknovitz
ITIsaac B. Thorman
Isaac B. Thorman
DWDinusha Wanniarachchige
Dinusha Wanniarachchige
ESEris Spirollari
Eris Spirollari
AJAnkita Jain
Ankita Jain
FAFawaz Al-Mufti
Fawaz Al-Mufti
BACKGROUND: Chronic subdural hematoma is a complex but commonly treated neurosurgical condition, particularly affecting the elderly. Traditional treatment involves open surgeries, but middle meningeal artery embolization (MMAE) has emerged as an effective, minimally invasive adjunctive. The objective of this study is to assess the safety and efficacy of MMAE in combination with surgery using real-world data. METHODS: This retrospective cohort study analyzed data from the TriNetX Research Network. Outcomes of mortality, reoperation, and hospital readmission were studied using Cox proportional hazard models controlling for age, sex, indications of severity, type of surgical intervention, antiplatelet/anticoagulant use, comorbidities, and hospitalization events. Patients were followed for up to 6 years. RESULTS: This study included 38 049 patients with chronic subdural hematoma, of which 486 received surgery with MMAE and 5362 received surgery monotherapy. At 90 days after surgery, mortality was 5.2% in the MMAE group and 7.7% in the surgery monotherapy group ( P =0.0467). After 6 years, mortality was 11.2% in the MMAE group and 19.0% in the surgery monotherapy group ( P <0.0001). However, the hazard of 90-day mortality was not significantly lower in the MMAE group after controlling for covariates (hazard ratio, 0.739 [95% CI, 0.479–1.141]; P =0.173). Patients with MMAE had significantly lower rates of rehospitalization at 1 year (2.1% versus 4.4%; P =0.0195), even after adjustment (hazard ratio, 0.414 [95% CI, 0.203–0.845]; P =0.015). CONCLUSIONS: Among patients with chronic subdural hematoma who received surgery, patients receiving adjunctive MMAE experienced lower mortality rates out to 6 years of follow-up, but the difference was not significant after full adjustment. Beginning 1 year after surgery, patients receiving combination therapy had significantly lower long-term rehospitalization compared with patients receiving surgery monotherapy. Future prospective studies will help identify strengths and weaknesses of this highly promising treatment modality.

17 October 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
ITIsaac B. Thorman
Isaac B. Thorman
EFEric Feldstein
Eric Feldstein
ASAriel Sacknovitz
Ariel Sacknovitz
AMAryan Malhotra
Aryan Malhotra
MSMichael C. Schubert
Michael C. Schubert
SWSteven Wolf
Steven Wolf